Cholesterol-Inflammation Combo Index Flags Heart Risk Before Disease Strikes

A single number that fuses two of cardiology’s most stubborn villains—remnant cholesterol and chronic low-grade inflammation—may help identify who is quietly heading toward a heart attack or stroke, even before any disease is diagnosed. That is the central claim of a new nationwide prospective cohort study from China, published in BMC Endocrine Disorders, which tracked more than 4,600 middle-aged and older adults for a median of seven years. The researchers, led by Wansong Hu, Huiming Zou and Ping Li of the Second Affiliated Hospital of Jiangxi Medical College, Nanchang University, constructed what they call the remnant cholesterol inflammatory index, or RCII, and asked a deceptively simple question: does this combined marker predict new-onset cardiovascular disease across the full spectrum of cardiovascular-kidney-metabolic syndrome, from apparently healthy people to those with overt metabolic risk factors?

The answer, according to the study, is a qualified yes. Participants in the highest quarter of baseline RCII values had a 36 percent higher risk of developing cardiovascular disease during follow-up than those in the lowest quarter, after the researchers statistically accounted for a long list of confounders including age, sex, blood pressure, diabetes status, kidney function, smoking and body mass index. The hazard ratio was 1.36, with a 95 percent confidence interval of 1.11 to 1.67 and a P value of 0.003, meaning the association was unlikely to be a statistical fluke. When the team adjusted the analysis for high-sensitivity C-reactive protein itself—the inflammatory component baked into the index—the estimate actually strengthened slightly, rising to a hazard ratio of 1.41, which suggests the signal is not simply an artifact of measuring inflammation twice.

To understand why this matters, it helps to unpack the two ingredients. Remnant cholesterol is the cholesterol carried in triglyceride-rich lipoproteins, the partially degraded leftovers of very-low-density lipoproteins and chylomicrons that circulate after a meal. Unlike LDL cholesterol, which has dominated cardiovascular prevention for decades, remnant particles are small enough to slip into the arterial wall and are thought to be particularly adept at triggering the fatty plaques that underlie atherosclerosis. High-sensitivity C-reactive protein, meanwhile, is the blood’s most widely used barometer of systemic inflammation, and elevated levels have long been linked to cardiovascular events independently of cholesterol. By combining the two into a single index, the authors aimed to capture a dual burden: the metabolic insult of cholesterol-rich remnant particles and the inflammatory response they provoke.

The study drew its participants from the China Health and Retirement Longitudinal Study, known as CHARLS, a nationally representative survey of Chinese adults aged 45 and older that has become one of the most valuable resources for studying aging and chronic disease in the world’s most populous country. Of the 4,606 adults included in the baseline analysis, 791 went on to develop cardiovascular disease over a median follow-up of 7.0 years. The researchers classified everyone according to the cardiovascular-kidney-metabolic syndrome staging framework, a relatively new scheme promoted by the American Heart Association that ranges from stage 0, meaning no metabolic risk factors at all, through stages 1 to 3, which encompass excess body fat, metabolic risk factors such as hypertension and diabetes, and kidney disease. Crucially, the elevated RCII signal held across all of these stages, from the apparently healthy to the already at-risk.

One of the study’s more intriguing technical findings concerns the shape of the relationship. Using a statistical technique called restricted cubic splines, which allows the data to reveal curves rather than forcing them into straight lines, the researchers found that the association between baseline RCII and cardiovascular risk was nonlinear, with a P value for nonlinearity of 0.002. In practical terms, this means the risk does not climb steadily with each incremental rise in the index. Instead, the analysis suggests a threshold-like pattern in which risk accelerates at higher values of the index, a shape that could have implications for how such a marker might eventually be used in clinical screening, since it hints at a range above which the index becomes most informative.

But the study also delivers a sobering lesson in epidemiological humility. Because a single blood measurement at baseline might miss how a person’s cholesterol and inflammation levels fluctuate over the years, the team also calculated a cumulative RCII, averaging repeated measurements across survey waves. They then performed a landmark analysis, restarting the clock in 2015 and following only the 4,129 participants who were still free of cardiovascular disease at that point. Among these, 449 developed cardiovascular disease, and this time the association fell short of statistical significance: the highest versus lowest cumulative RCII quartile yielded a hazard ratio of 1.17, with a confidence interval of 0.89 to 1.54 that comfortably includes the null value of 1.0, and a P value of 0.275.

That discrepancy between the baseline and cumulative analyses is more than a statistical footnote; it is a window into how risk markers can behave differently depending on how they are measured. One plausible interpretation is that a single, sharply elevated measurement captures an acute or sustained metabolic-inflammatory state that is genuinely dangerous, whereas averaging values over time dilutes the signal, blending high-risk periods with calmer ones. Alternatively, the smaller number of events in the landmark cohort—449 versus 791—reduced the statistical power available to detect a real effect, so the cumulative result may reflect insufficient data rather than a truly absent association. The authors are careful to frame RCII as a candidate risk marker rather than a validated clinical tool, and the cumulative finding underscores why such caution is warranted.

The researchers also probed whether the association varied across subgroups defined by age, sex, hypertension, diabetes and other characteristics, and found no significant interactions, meaning the elevated index appeared to carry similar prognostic weight across these strata. That consistency is encouraging for a potential biomarker, because a measure whose meaning shifts dramatically between patient groups is far harder to deploy in practice. It also aligns with the broader conceptual appeal of the cardiovascular-kidney-metabolic framework itself, which was designed to encourage clinicians to see heart disease, kidney dysfunction and metabolic disorders as an interconnected continuum rather than separate silos. A marker that integrates a metabolic lipid abnormality with inflammation fits naturally into that unified view of risk.

Several caveats temper the excitement. This is an observational study, so it can demonstrate association but not prove that a high RCII causes cardiovascular events; it remains possible that unmeasured factors drive both the index and the outcomes. The cohort consists of Chinese adults aged 45 and older, and whether the findings generalize to younger populations or to other ethnic groups is unknown. The index itself is a derived composite, and its exact formulation would need standardization and external validation in independent cohorts before it could inform screening guidelines or treatment decisions. And although remnant cholesterol can be estimated from standard lipid panels using the Friedewald-style calculation, its accuracy depends on fasting status and triglyceride levels, adding practical wrinkles to any future clinical rollout.

Still, the study adds a compelling piece to a rapidly evolving puzzle. Cardiovascular disease remains the leading cause of death worldwide, and a substantial share of events occurs in people whose conventional risk factors appear unremarkable, fueling the search for markers that reveal hidden risk. Remnant cholesterol has surged in scientific prominence in recent years as genetic and mechanistic studies have implicated it in atherosclerosis independently of LDL, and inflammation has been validated as a therapeutic target by landmark trials of anti-inflammatory drugs. An index that marries the two is a logical next step, and the finding that it predicts incident cardiovascular disease across cardiovascular-kidney-metabolic stages 0 through 3, with a nonlinear dose-response and robustness across subgroups, marks it as a candidate worth watching. If future studies confirm these results and clarify the ambiguous cumulative signal, the humble arithmetic of combining two routine blood tests could one day help clinicians catch cardiovascular danger years before the first symptom appears.

Subject of Research: Association between the remnant cholesterol inflammatory index and incident cardiovascular disease risk across cardiovascular-kidney-metabolic syndrome stages

Article Title: Association of remnant cholesterol inflammatory index and cardiovascular risk among individuals across cardiovascular-kidney-metabolic syndrome stages 0–3: a nationwide prospective cohort study

Article References: Hu, W., Zou, H., & Li, P. (2026). Association of remnant cholesterol inflammatory index and cardiovascular risk among individuals across cardiovascular-kidney-metabolic syndrome stages 0–3: a nationwide prospective cohort study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02590-7

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02590-7

Keywords: remnant cholesterol, inflammation, cardiovascular disease, cardiovascular-kidney-metabolic syndrome, C-reactive protein, biomarker, cohort study, CHARLS, atherosclerosis, risk prediction, metabolic syndrome, epidemiology